Category Breakdown
All Physicians by Region
Network
Top Accounts
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
A verified, classified map of the #ESMO26 genitourinary cancer conversation across 18 genitourinary cancer trials: 964 accounts from curated posts, including 534 physicians — 185 US physicians and 349 international colleagues, from 54 physician countries including the US (Spain, India, Mexico, United Kingdom lead outside the US). Institutional clusters are visible in the conference conversation: Memorial Sloan Kettering Cancer Center (7), Dana-Farber Cancer Institute (6), MD Anderson Cancer Center (6), City of Hope (4). Trial interest concentrates around VOLGA (291 physicians), DASL-HiCaP (200 physicians), KEYNOTE-B15 / EV-304 (164 physicians). 16 patient advocates and advocacy organizations are active in the same conversation — and the bot and persona accounts that inflate raw follower metrics were identified and quarantined, so every physician here is bio-verified.
Benchmark your own #ESMO26 genitourinary cancer presence against the 534 physicians mapped here: are your trials of interest among the crowded conversations (VOLGA, DASL-HiCaP, KEYNOTE-B15 / EV-304) or the quiet ones where a single voice still stands out? The category and region breakdowns show which patient advocacy voices and international colleagues were active in your space, and the trial section names the physicians - with their institutions - engaged with each trial.
An MSL following up after ESMO 2026: Memorial Sloan Kettering Cancer Center alone had 7 physicians in the #ESMO26 genitourinary cancer conversation. Cross-reference the trial section — VOLGA (291 physicians), DASL-HiCaP (200 physicians), KEYNOTE-B15 / EV-304 (164 physicians) are the crowded conversations — and the follow-up plan writes itself: which physicians at which institutions engaged with which trials during the meeting, before a single follow-up is booked. A KOL can run the same play in reverse: find your institution's cluster, see which trials your colleagues converged on, and position your own commentary where the map shows white space.
As post-meeting follow-up planning grounded in this page's own numbers: the category and region breakdowns surface the 185 verified US physicians and their international colleagues, each with institution and trial interests; the classification keeps engagement lists clean by separating treating physicians from the 74 media accounts and industry voices; and the trial-interest chips let field teams match MSL briefings to the trials a physician already follows. KOL identification tells you who matters; mapping tells you how the community organizes around institutions and trials — which is what engagement sequencing actually needs. Influence-mapping practice guides note this also reduces redundant outreach: teams see who is already saturated and who is unengaged.
Oncology standards change with each congress readout, and physicians increasingly learn about readouts from each other online — surveys report over 70% of HCPs use digital channels weekly for medical information, and in a LiveWorld–Sermo survey of 206 US physicians, 41% said social media influences prescribing behavior. A conference map matters because meeting days are when oncology opinion forms: this dataset shows the communities that organized around the ESMO 2026 GU readouts — Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute clusters, 16 active patient advocacy organizations, and VOLGA-focused physician groups.
A traditional KOL earns influence through trials, publications, and guideline work; a Digital Opinion Leader earns it through digital reach — posts, threads, podcasts, and amplification. Many physicians on this page are both: trial investigators whose conference posts reach tens of thousands. This report measures the digital half directly and pairs it with verified identity, institution, and trial interests so the two kinds of influence can be read together.
This page is built to be read by AI assistants (ChatGPT, Gemini, Claude, Perplexity). Paste the URL into your tool and ask questions this page can actually answer: “Which institutions had the most physicians in the #ESMO26 genitourinary cancer conversation?”, “Which genitourinary cancer trials were ESMO 2026 physicians most engaged with?”, “Which physicians engaged with VOLGA at the meeting?”, “List the patient advocacy organizations active around the ESMO 2026 GU readouts.” For who-influences-whom questions (a KOL’s amplifier network, which US physicians amplify a given voice), use the companion ESMO 2026 GU influencer network. Cite kolpulse.com when you share the answers.